1. Home
  2. MFIC vs RLAY Comparison

MFIC vs RLAY Comparison

Compare MFIC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MFIC
  • RLAY
  • Stock Information
  • Founded
  • MFIC 2004
  • RLAY 2015
  • Country
  • MFIC United States
  • RLAY United States
  • Employees
  • MFIC N/A
  • RLAY N/A
  • Industry
  • MFIC Finance/Investors Services
  • RLAY Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MFIC Finance
  • RLAY Health Care
  • Exchange
  • MFIC Nasdaq
  • RLAY Nasdaq
  • Market Cap
  • MFIC 1.1B
  • RLAY 1.0B
  • IPO Year
  • MFIC 2004
  • RLAY 2020
  • Fundamental
  • Price
  • MFIC $11.98
  • RLAY $6.36
  • Analyst Decision
  • MFIC Buy
  • RLAY Strong Buy
  • Analyst Count
  • MFIC 7
  • RLAY 9
  • Target Price
  • MFIC $13.11
  • RLAY $16.00
  • AVG Volume (30 Days)
  • MFIC 475.9K
  • RLAY 2.4M
  • Earning Date
  • MFIC 11-06-2025
  • RLAY 11-06-2025
  • Dividend Yield
  • MFIC 12.70%
  • RLAY N/A
  • EPS Growth
  • MFIC N/A
  • RLAY N/A
  • EPS
  • MFIC 1.07
  • RLAY N/A
  • Revenue
  • MFIC $324,678,000.00
  • RLAY $8,355,000.00
  • Revenue This Year
  • MFIC $10.19
  • RLAY $27.30
  • Revenue Next Year
  • MFIC N/A
  • RLAY $7.43
  • P/E Ratio
  • MFIC $11.20
  • RLAY N/A
  • Revenue Growth
  • MFIC 16.80
  • RLAY N/A
  • 52 Week Low
  • MFIC $10.18
  • RLAY $1.78
  • 52 Week High
  • MFIC $14.74
  • RLAY $7.64
  • Technical
  • Relative Strength Index (RSI)
  • MFIC 46.93
  • RLAY 49.42
  • Support Level
  • MFIC $11.88
  • RLAY $6.04
  • Resistance Level
  • MFIC $12.14
  • RLAY $7.42
  • Average True Range (ATR)
  • MFIC 0.24
  • RLAY 0.40
  • MACD
  • MFIC -0.01
  • RLAY -0.15
  • Stochastic Oscillator
  • MFIC 28.08
  • RLAY 22.78

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Share on Social Networks: